5-Azacytidine treatment of the patient with ATMDS
Daniel B. Costa,
Daniel B. Costa
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author Christopher A. Fisher,
Christopher A. Fisher
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Kenneth B. Miller,
Kenneth B. Miller
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author German A. Pihan,
German A. Pihan
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author David P. Steensma,
David P. Steensma
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
Search for more papers by this author Richard J. Gibbons,
Richard J. Gibbons
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Douglas R. Higgs,
Douglas R. Higgs
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author
Daniel B. Costa,
Daniel B. Costa
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author Christopher A. Fisher,
Christopher A. Fisher
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Kenneth B. Miller,
Kenneth B. Miller
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author German A. Pihan,
German A. Pihan
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author David P. Steensma,
David P. Steensma
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
Search for more papers by this author Richard J. Gibbons,
Richard J. Gibbons
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Douglas R. Higgs,
Douglas R. Higgs
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author
First published: 06 April 2006
Daniel B. Costa MD, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Av., Rabb 430, Boston, MA 02215, USA
Tel: (617)-667-9138
Fax: (617)-667-9919
e-mail:
[email protected] No abstract is available for this article.
Reference
- 1
Costa DB,
Fisher CA,
Miller KB,
Pihan GA,
Steensma DP,
Gibbons RJ,
Higgs DR.
A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome.
Eur J Haematol
2006; 76: 432–435.
